Inadequate response to antidepressant treatment, in a significant proportion of patients
diagnosed with Major Depressive Disorder, contributes to the large burden of disability …

Clinical trials and real-world data have shown that long-acting injectable antipsychotics
(LAIs) might be an effective therapeutic option also for people with bipolar disorder (BD) …

Introduction: In this review, the authors discuss the role of long-acting injectable
antipsychotics (LAIs) for schizophrenia, focusing on the effectiveness and new perspectives …

Background Mood recurrences in bipolar disorder (BD) are often associated with poor
treatment adherence. Despite long-acting injectable antipsychotics (LAIs) may favor …

This retrospective study evaluated the benefit of following different long-acting injectable
(LAI) initiation strategies based on the timing of behavioral and clinical events among …

Background: The use of therapeutic drug monitoring (TDM) to guide treatment with long-
acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of …

Background: Personal resources have been identified as important factors in predicting
patient healing or symptoms control in schizophrenia. This observational retrospective study …

Schizophrenia is a severe mental illness causing a high degree of disability. First-and
second-generation antipsychotics (FGAs and SGAs) represent key resources for its acute …

Introduction Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics
in the real world is lacking. In this study, we aimed to identify the sociodemographic and …

Introduction Patterns of clinical use of long‐acting injectable (LAI) antipsychotic drugs in
many countries, especially in Asia, for treatment of patients diagnosed with chronic psychotic …